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Résumé 
L’utilisation de nanovecteurs pour la livraison contrôlée de principes actifs est un concept 
commun de nous jours. Les systèmes de livraison actuels présentent encore cependant des 
limites au niveau du taux de relargage des principes actifs ainsi que de la stabilité des 
transporteurs. Les systèmes composés à la fois de nanovecteurs (liposomes, microgels et 
nanogels) et d’hydrogels peuvent cependant permettre de résoudre ces problèmes. Dans cette 
étude, nous avons développé un système de livraison contrôlé se basant sur l’incorporation 
d’un nanovecteur dans une matrice hydrogel dans le but de combler les lacunes des systèmes 
se basant sur un vecteur uniquement. Une telle combinaison pourrait permettre un contrôle 
accru du relargage par stabilisation réciproque. Plus spécifiquement, nous avons développé un 
hydrogel structuré intégrant des liposomes, microgels et nanogels séparément chargés en 
principes actifs modèles potentiellement relargués de manière contrôlé. Ce contrôle a été 
obtenu par la modification de différents paramètres tels que la température ainsi que la 
composition et la concentration en nanovecteurs. Nous avons comparé la capacité de 
chargement et la cinétique de relargage de la sulforhodamine B et de la rhodamine 6G en 
utilisant des liposomes de DOPC et DPPC à différents ratios, des nanogels de chitosan/acide 
hyaluronique et des microgels de N-isopropylacrylamide (NIPAM) à différents ratios d’acide 
méthacrylique, incorporés dans un hydrogel modèle d’acrylamide. Les liposomes présentaient 
des capacités de chargement modérés avec un relargage prolongé sur plus de dix jours alors 
que les nanogels présentaient des capacités de chargement plus élevées mais une cinétique de 
relargage plus rapide avec un épuisement de la cargaison en deux jours. Comparativement, les 
microgels relarguaient complétement leur contenu en un jour. Malgré une cinétique de 
relargage plus rapide, les microgels ont démontré la possibilité de contrôler finement le 
chargement en principe actif. Ce contrôle peut être atteint par la modification des propriétés 
structurelles ou en changeant le milieu d’incubation, comme l’a montré la corrélation avec les 
isothermes de Langmuir. Chaque système développé a démontré un potentiel contrôle du taux 
de relargage, ce qui en fait des candidats pour des investigations futures.  
Mots-clés : Livraison contrôlée, hydrogel, liposome, microgel, nanogel. 
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Abstract 
Controlled delivery of active compounds using nanoscale carriers is nowadays a 
common concept, but there are still limitations in current delivery systems related to active 
compound release rate and nanocarriers stability. To address these limitations, delivery 
systems can be made to incorporate both nanocarriers (liposomes, microgels and nanogels) 
and hydrogels. In this study, we have developed controlled delivery systems by combining 
different carriers in order to overcome deficiencies observed in systems using only one type of 
carrier. Such a combination could lead to an enhanced controlled release delivery system 
through synergistic stabilization. More specifically, we created a structured hydrogel 
embedded with either liposomes, microgels, or nanogels, each loaded with model active  
compounds that would be released in a controlled fashion by manipulating  
the temperature of release medium and nanocarriers composition and concentration. We 
compared drug loading and release kinetics of sulforhodamine B from liposomes (composed 
of DOPC and DPPC at different ratios) and nanogels (chitosan/hyaluronic acid) embedded in 
acrylamide hydrogels. We also compared drug loading and release kinetics of rhodamine 6G 
from microgels of N-isopropylacrylamide (NIPAM) with different ratios of methacrylic acid 
embedded in acrylamide hydrogel. Liposomes demonstrated a moderate drug loading capacity 
with sustained release for over ten days, while nanogels showed high drug loading but faster 
release kinetics, exhausting their contents within two days. Comparatively, microgels 
completely released their content within a day. Despite their faster release kinetics, microgels 
have shown the capacity to be finely tuned for efficient drug loading. The Langmuir isotherms 
indicated that it can be achieved by altering their structural properties or by changing their 
incubation medium. Each developed system has demonstrated a potential in controlling the 
release rate, which makes them candidates for further investigations in the future. 
 
Keywords : Controlled delivery, hydrogel, liposome, microgel, nanogel. 
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Chapter 1 : Introduction 
 
1.1. Introduction  
Active compound (AC) delivery research is one of the most rapidly developing, 
interdisciplinary fields in science. It is a collaboration between biomedical scientists and 
health practitioners in order to improve human health care. Advances in active compound 
delivery systems has led to further improvements in pharmacological activity of different AC 
dosage forms that had previously limited pharmacokinetic and biodistribution properties. 
Employment of AC carriers like liposomes, polymeric nanoparticles, and hydrogels has 
proven to be of importance in developing a controlled delivery system (2-4).  Therefore, one 
of the main approaches is to design a system capable of improving AC efficacy at target 
tissues, while minimizing its toxicity at healthy tissues (5). A delivery system should be 
optimized for AC efficacy since it will affect the AC’s pharmacokinetic properties, target of 
action, and side effects.  
 
Hydrogels and liposomes were found to be effective carriers for controlled delivery of 
multiple active compounds. For instance, anticancer agents (6-8), genetic materials (9-11), and 
interestingly, growth factors (12-14) that can play a major role in tissue engineering. However, 
studies found that there are some issues associated with using conventional liposomes alone, 
including short circulation half-life (t1/2) due to rapid uptake by the reticuloendothelial system 
(15), difficulty in controlling loading and release rate of AC (16-18). Similarly, hydrogels 
have shown many advantages in different fields, especially in tissue engineering and 
regenerative medicine but rapid burst release of ACs is a common problem associated with 
hydrogels as a single delivery system (19-22). Combining AC nanocarriers and hydrogel in a 
single delivery system could have the potential to create a better controlled delivery, while 
also addressing concerns about the deficiencies of the individual AC carriers. 
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1.2. Hydrogels as effective carriers for AC controlled delivery 
system  
Hydrogels have taken on several different definitions since their discovery in 1960 by 
Wichterle and Limwere (23). The most commonly used definition describes hydrogels as two- 
or several components system composed of polymeric chain networks containing water that 
fills hydrogel gaps while remaining insoluble in aqueous media (24). Classification of 
hydrogel is based on several factors like polymeric composition (mono-polymer or co-
polymer) (25), cross-linking method (physically or chemically cross-linked) (26-30), reactivity 
towards external and physiological stimuli (temperature, pH, magnetic field) (31, 32), and 
source (natural or synthetic polymers) (33, 34). Moreover, developments in hydrogel 
technology has lead to increasing its use in the pharmaceutical industry (35). 
Hydrogels fabricated from naturally-sourced polymers have multiple advantages making 
them suitable for pharmaceutical and biomedical applications. Natural polymeric hydrogels 
usually have better biocompatibility and biodegradability compared to synthetic polymers 
(36). However, some of these hydrogels do not offer appropriate mechanical features for 
carrying ACs. Also, they could alter the immune system and cause an inflammatory reaction 
from pathogens inadvertently embedded in the polymer moieties (37). Alternatively, synthetic 
hydrogels have polymeric structures that are modifiable to produce the desired mechanical 
features and degradation kinetics (38-40).  
 
1.3. Hydrogels technologies for improving AC controlled delivery 
system  
Hydrogels for AC controlled delivery goal should have well-defined biodegradability 
and biocompatibility properties. As a result, there is an increased urge for developing novel 
and optimized delivery methods. So far, several approaches have been developed to create 
such hydrogels by manipulating particular parameters, as will be discussed in this section. 
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1.3.1. Biomimetic hydrogels  
Recently, it has been suggested that hydrogel scaffolds as an extra-cellular matrix that 
mimic normal tissues could improve AC delivery (41-43). As a result, several different 
fabrication methods have been developed to synthesize such scaffolds (20, 44, 45). Initially, 
two-dimensional (2D) polymeric scaffolds were used along with adhesive AC for controlled 
delivery (46, 47). A method was developed based on creating a molecular concentration 
gradient in the ECM embedding ACs like proteins, macromolecules as chemokines and 
growth factors (48). Gradient materials were shown to enhance different cellular actions such 
as cellular proliferation, ex vivo migration, and transmission of signals (49, 50). For example, 
a microfluidic gradient instrument composed of poly(ethylene glycol) diacrylate hydrogels 
was created and placed with MC3T3-E1 cells to generate concentration gradient of okadaic 
acid as an AC model released by diffusion (51).  
 
 Following that, three-dimensional (3D) hydrogel scaffolds were developed for 
improving AC controlled delivery and release through simulating 3D tissues structure. 
Hydrogels as 3D scaffolds have become very effective in enhancing cell growth, 
differentiation and organization (52, 53). Several methodologies were developed for 
embedding AC or cells within hydrogel scaffolds. For instance, one of the primary methods 
uses cells were embedded within the hydrogel by introducing them during gelation process. 
An experiment was carried out using human corneal epithelial cells to determine their capacity 
to survive within calcium alginate-hydroxyethyl cellulose hydrogel. Results showed that 
insertion of the cells during gelation process did not affect cells activity and survived for seven 
days at different temperatures. These results revealed that hydrogel can be beneficial to 
cellular mobilization and storage purposes (54). 
 
 A second study discussed the same technique but examined the impact of manipulating 
hydrogel components over embedded neural stem cells. They incorporated fluorinated 
methacrylamide chitosan hydrogels containing scaffold elements as ECM to test cells 
differentiation. According to the study, it had been suggested that Fluorine components in the 
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hydrogel had a significant role in adjusting oxygen level within the medium, which, 
significantly enhanced the differentiation of embedded cells (55).  
   
 Moreover, a new technique making use of niches within alginate hydrogel before 
embedding hepatocarcinoma cells (HepG2) (56). Gelatin beads of various known diameters 
were used to create the niches. After that, cells were implanted inside these scaffold cavities 
and had apparently improved cell proliferation in comparison to scaffolds with no porosity due 
to superior mass transfer of nutrients and oxygen into the hydrogel. 
 
The lifespan of cells in human tissues are largely influenced by the physical stress, 
biochemical and physiological properties of the surrounding ECM. Therefore, controlling 
spatiotemporal factors of ACs and their interaction with cells within tissues are the key to 
initiate biochemical reactions between them. Using hydrogels as an effective carrier for tissue 
engineering can provide a combination of cellular encapsulation and triggered release of active 
compounds to enhance temporally controlled cell growth. For example, a hierarchical porous 
structure of chitosan hydrogel demonstrating consistent network of pores was developed (57). 
The hydrogel was prepared by gas foaming after encapsulating CaCO3 microparticles of 10 
µm diameter. Then, the hydrogels were freeze-dried to obtain the hierarchical porous structure 
where molecules of differing charges of chondroitin and chitosan were placed in alternating 
order to obtain an ECM. In addition, fibroblast growth factors as well as pulmonary fibroblast 
cells of human origin were loaded into the pores by chondroitin sulfate binding. The results 
suggested that the network structural design did not negatively impact cumulative release of
 
fibroblast growth factors, and succeeded in supporting cell proliferation by enhancing their 
loading and promoted their delivery to pulmonary fibroblast cells (57). 
 
Hydrogel scaffolds were tested in injured mice skeletal muscle tissue in vivo. The 
experiment started with mixing alginate hydrogel materials with vascular endothelial growth 
factor and insulin-like growth factor before gelation procedure takes place as loading method. 
Next, the mixture was freeze-dried to design niches in the scaffolds in order to embed 
myoblast cells and to test the scaffold capability for improving muscular tissue regeneration. 
The authors expressed that vascular endothelial growth factor and insulin-like growth factor 
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have provided a significant synergistic effect in regenerating damaged tissues. Also, upon 
loading myoblast cells within the hydrogel, niche scaffolds were more effective for fiber 
regrowth and improved vascular tissues density, which lead to better healing (58). 
In contrast to the above-mentioned methods, a different technique, with implications in 
orthopedic medicine, based on passive release was developed to facilitate AC interaction with 
adjacent cells release. They created polyethylene glycol (PEG) scaffolds embedding 
dexamethasone via peptide linker to release AC locally into sites where adjacent human 
mesenchymal stem cells located. Following that, metalloproteinase were released from stem 
cells, which breaks down the peptide linkers and suppresses cellular reactions in the hydrogel 
(59). 
 1.3.2. Biodegradable hydrogels  
Biodegradable hydrogels are preferred over non-degradable hydrogels as carriers 
within designed conditions because they allow one to control their degradation rate. 
Consequently, biodegradable hydrogels eliminate the need for surgical extraction after implant 
procedures (60). However, certain factors and methods during hydrogel fabrication are 
required to anticipate the degradation levels such as the type of polymer or employing more 
than one type of polymers with different properties. These factors and techniques are essential 
in order to achieve optimal controlled release of ACs in implants and tissue regeneration. 
Hydrolytically degradable hydrogels of PLA-b -PEG-b –poly(lactic acid) (61) have been 
created using block copolymers of PLA and PEG for protein delivery purposes (62). The 
degradation rates were investigated in order to determine AC release and diffusion by focusing 
on certain macroscopic parameters like compressive strength and swelling ratio (63-65). Also, 
biological moieties have been incorporated into synthetic hydrogels, which allows them to be 
broken down by enzymes. Peptide substrates were used not only to fabricate biodegradable 
hydrogel, but also to tailor the rate of degradation and release of ACs (66). For example, in a 
system created to simulate ECM and its surrounding cells, binding sites were created using 
integrin and peptide substrates for breakdown by matrix metalloprotease. After that, cells 
penetrate the hydrogel matrices by matrix metalloproteinase excretion (67, 68).   
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Another method was developed using a synthetic protein with a degradable matrix to 
enhance embedding of cells within the hydrogel. The protein has two receptors (RGD integrin 
and heparin) for cells to attach and two plasmin sites designed to degrade the medium to 
enhance cell diffusion. The protein has been used in parallel with poly(ethylene glycol) 
diacrylate to synthesize the hydrogel as ECM encapsulating human fibroblasts-fibrin clusters. 
Results showed that cell proliferation had been achieved for about seven days while promoting 
cellular diffusion within the hydrogel (69). 
 
1.3.3. Smart “stimuli-responsive” hydrogels  
Stimuli-responsive hydrogels differ from other types of hydrogels in term of their 
sensitivity to the external parameters like temperature and pH, that affect the rate of swelling 
of these hydrogels (70). As such, changes in the volume capacity makes this type of hydrogels 
effective as a controlled delivery system, as the release rate of ACs is adjustable by 
manipulating external physical parameters (71-73). pH sensitive hydrogels based on pH-
sensitive polymers are commonly known as polyelectrolytes. Mostly, polymers used for this 
purpose include poly(acrylic acid) (PAA) and poly(N,N′-diethylamino ethyl methacrylate) 
(PDMAEM), which are sensitive to low and high pH respectively (61, 74, 75). As a result, 
they show different swelling behaviors when fabricated in different pH media. However, 
employing neutral co-monomers like 2-hydroxyethyl methacrylate, methyl methacrylate and 
maleic anhydride in pH-sensitive hydrogels can modify and control their pH sensitivity, rate of 
swelling, and consequently AC release rate (76-78).  
 
Polyelectrolyte hydrogels are widely used for controlling AC release in oral dosage 
forms because of pH variability along the gastrointestinal tract (77), (79). The method 
involves embedding caffeine in a hydrogel using copolymers of N,N′-dimethylamino ethyl 
methacrylate (DMAEM) and methyl methacrylate (MMA).  The release of caffeine from 
hydrogel is only triggered at acidic pH but not at neutral or basic media due to DMAEM 
sensitivity and ionization at low pH (79).  
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Thermo-sensitive hydrogels are fabricated from different polymeric materials like 
poly(N-isopropylacrylamide) (pNIPAM) and Poly(N,N-diethylacrylamide) (PDEA) (80-82). 
PDEA has been found to be more beneficial due to its lower critical solution temperature 
LCST, which is relatively close to physiological temperature (83, 84). Unlike the majority of 
polymers, the water solubility of LCST polymers decrease with increasing temperature which 
results in hydrogel shrinking (85). The inverse relationship between changes in temperature 
and swelling rate are due to polymer chains that have either hydrophobic groups or 
combination of hydrophilic and hydrophobic segments. Hydrogen bonds between aqueous 
solution molecules and hydrophilic segments are strengthened once the temperature decreased 
and thus increases polymers dissolution. On the other hand, at higher temperature the 
hydrogen bonds dissociate and hydrophobic interactions between hydrophobic segments 
dominate, leading hydrogel shrinking (71). 
 
 In order to achieve better control over the swelling and shrinking rate of LCST 
hydrogels, a technique was developed that modifies hydrophilic and hydrophobic segments 
ratios by creating copolymers using NIPAM composed of acrylic acid as hydrophobic and 
hydrophilic monomers respectively (86-88). Applying such method will alter LCST and lead 
to hydrogels with improved features like responsiveness toward other stimuli and increased 
shrinking rate upon rising temperature (89). Furthermore, additional types of block 
copolymers composed of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) share 
the same features as PDEA in that they have a lower critical solution temperature which can 
be used to deliver ACs over controlled period of time. Pluronics® (or Poloxamers) is an 
example of applicable in-situ thermo-sensitive hydrogel using PEO–PPO block copolymers 
(72, 90).  
 
There are some limitations associated with temperature-sensitive hydrogels using 
NIPAM for biomedical applications because of issues related to its biodegradability and its 
metabolism (72). Also, there is a concern related to hydrogels based on acrylamide due to 
acrylamide’s ability to activate platelets once it is in blood stream (91).  
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1.4. Nanocarriers for AC controlled delivery system 
Significant advances in nanotechnology has led to the development of nanoscale 
carriers with specific physical and chemical properties beneficial for therapeutic purposes 
(92). Nanocarriers involved in therapeutic applications have been found advantageous in 
improving controlled delivery of ACs (93). Also, they enhance AC bioavailabity by altering 
its pharmacokinetic properties and its biodistribution. They may be used as reservoirs for 
prolonged release in vivo, that is, increasing circulation half-life, and decreasing toxicity of 
ACs (table 1.1) (94).  
Several nanoparticles (NPs) such as polymeric NPs, lipid based NPs (liposomes or 
micelles), polymer-active compound conjugates, and dendrimers have therapeutic applications 
(95-97). Nevertheless, choosing the appropriate nanocarier for a specific AC depends on the 
characteristics of the AC itself, like its potency, shelf life, solubility in different mediums, 
biochemical charge, and molecular weight (98).  
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Table 1.1. Common issues related to AC using regular dosage forms, and the potential 
improvement using nanocarriers (9, 99-103) 
Common problems related to AC regular 
dosage forms 
Impact of nanocarriers as delivery system 
Low solubility of AC. Some dosage forms 
are hard to develop like hydrophobic AC in 
hydrophilic media. 
Micelles and liposomes encapsulate 
hydrophobic and hydrophilic AC. 
Tissue toxicity of AC, e.g. (tissue necrosis 
associated with free doxorubicin). 
Controlled release from NPs decreases or 
eliminates tissue toxicity. 
Unwanted pharmacokinetics of AC. Some 
AC dosage forms experience rapid kidney 
elimination. 
Rapid renal elimination is decreased with 
small NPs. 
Weak biodistribution of AC. Dose limiting 
side effects associated with expanded AC 
distribution in some dosage forms. 
NPs decrease distribution volume and 
minimize side effect at non target site 
Lack of selectivity of AC in some dosage 
forms lead to low AC concentration at target 
site. 
NPs enhance selectivity and concentration by 
ligand-mediated targeting as well as enhanced 
permeability retention effect respectively 
 
1.4.1. Polymer- active compound conjugates  
This type of nanocarrier is used with ACs like proteins and is characterized by having 
a small molecular weight and non-targeted activity. As a result, this will lead to longer t1/2 in 
vivo up to several hours with minimized unwanted side effects through reduction of 
endocytosis (passive delivery) (104-106). Polysaccharide, polyallylamine hydrochloride, and 
PEG were the first polymers found to be effective and have been introduced as nanocarriers 
(107). However, some disadvantages were noticed with these polymers (except PEG. Table 
1.2), such as poor biodistribution, short t1/2, toxicity, weak AC carrying capability, and fast 
release (92).  
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Table 1.2. Different types of PEG-conjugates in clinical use. 
 
1.4.2. Polymer nanoparticles  
Polymer nanoparticles production occurs through spontaneous formation of 
copolymers composed of several polymer blocks with variable hydrophobic ratios (114). 
Copolymers self-assemble into NPs, exhibiting a hydrophobic core-shell micelles (115). Such 
nanoparticles are able to carry small amounts of hydrophobic and hydrophilic active 
compounds. They can also encapsulate macromolecules like protiens (116, 117). The most 
frequently employed polymers to synthesize nanoparticles are poly D,L-lactic acid, poly D,L-
glycolic acid, and poly Σ-carpolactone along with copolymers in different ratios surrounded 
by PEG (118, 119). Many techniques through which the controlled release can be achieved, 
such as polymers side chain alteration, and copolymer synthesis development (120-123). 
Abraxane® and Zevalin® are examples of commercially available NPs for medical 
applications (124). 
 
PEG-Conjugates Brand name Medical indication 
PEG-adenosine 
deaminase  
Adagen Sever combined immunodeficiency with 
adenosine deaminase deficiency (108).  
PEG-anti-VEGF 
aptamer 
Macugen Macular degeneration (109). 
PEG-alfa-interferon 2a Pegasys Hep A, Hep C (110). 
PEG-GCSF Neulasta Neutropnia with cancer chemotherapy 
(111). 
PEG-HGF Somavert Acromegally (112).  
PEG-L-asparaginase Oncaspar Acute lymphoblastic leukemia ALL (113). 
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1.4.3. Liposomes for AC controlled delivery system 
After Alec Bangham discovered liposomes 40 years ago, liposomes have become 
ubiquitous in medical and pharmaceutical research as a fundamental tool in AC controlled 
delivery systems. Liposomes are lipid-based nanoparticles, 100 – 5000 nm in diameter, 
composed of a bi-layered vesicle with a hydrophilic core (125). The basic building blocks of 
liposomes are amphiphilic molecules such as phospholipids. These phospholipids have 
hydrophilic heads composed of phosphoric acid with a hydrophobic tail consisting of two 
chains of fatty acids, 10-24 carbon atoms in length, with 0-6 double covalent bonds in every 
chain (figure 1.1) (126, 127). Liposome formation is initiated through phospholipid hydration 
in water while applying multiple energy inputs of heating and sonication. Moreover, this 
process can lead to the formation of lamellar sheets in which hydrophilic heads are facing the 
aqueous area, while hydrophobic chains are facing each other, forming a-vesicle like structure 
with a hydrophilic core (128).  
 
 
Figure 1.1. Schematic diagram of phospholipids and liposome structure. 
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Liposomes can be classified according to size, structure, and quantity of bilayers. 
Nevertheless, the discussion will focus on classification in terms of size and bilayers quantity 
exclusively into multilamellar vesicle (MLV), large unilamellar vesicle (LUV), and small 
unilamellar vesicle (SUV) as described in figure 1.2.   
 
 Multilamellar vesicles (MLV) 
These types of liposomes are greater than 100 nm in size and contain two or more 
bilayers. MLV are prepared by slow rate thin film hydration method to improve active 
compound encapsulation and characterized by mechanical stability for extended duration 
(129). MLV elimination occurs rapidly through reticulo endothelial system (RES) because of 
its large size (130).  
 
Large unilamellar vesicle (LUV) 
Although LUV liposome has a similar size to MLV, it has only a single bilayer. Also, 
LUV requires only small amount of lipids to encapsulate a larger quantity or volume of 
hydrophilic AC comparing to MLV (130, 131). Freeze-thawing method is one among several 
methods to prepare such liposomes formulation (132, 133). Rapid RES elimination is still the 
predominant issue with this class of liposomes. 
 
Small unilalmellar vesicle (SUV) 
Usually, this class of liposomes is defined as having a diameter less than or equal to 
100 nm. They have low encapsulation efficiency and prolonged in vivo circulation in 
comparison to other types of liposomes. It is common to use an extrusion process for 
restricting the size to obtain SUV liposomes (134).  
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Figure 1.2. Schematic diagram of liposomes classification based on size and bilayers number. 
 
1.4.4. Liposomes technologies for AC controlled delivery system 
development  
In this section, applications and developed technologies to enhance liposomal 
efficiency will be discussed since liposomes were central to the project. 
 
1.4.4.1. Targeting liposomes for AC controlled delivery system 
Many ACs are well known for their systemic or localized toxicity due to their high 
potency and narrow therapeutic indexes. In order to achieve an optimal delivery to the affected 
sites without exposing other non-affected sites to further toxicity, formulating liposomes 
encapsulating active compounds has been suggested for better convenience and efficacy. 
Active and passive targeting mechanisms for creating targeting liposomes have been proposed 
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(135-137). For instance, a (passive/active mechanism) involving IgG Immunoglobulins and 
their segments has been commonly used in order to create targeting moieties in 
immunoliposomes without impacting their structural integrity. IgG Immunoglobulins attached 
to liposome surface via covalent bonds or inserted within liposome membrane through 
hydrophobic interaction (138). Despite developments in liposomal targeting, most liposomes 
undergo hepatic accumulation and metabolize due to their short t1/2 at targeted sites. 
Enhancing liposomal t1/2 would lead to improved interaction and accumulation at target sites 
instead of liver. 
 
1.4.4.2. Long circulating liposomes for AC controlled delivery system 
Several methods were suggested to manage controlled delivery and release rate that 
lead to prolonged, consistent, and effective therapeutic plasma level of ACs (139-141). They 
involve liposome surface modifications by altering liposome pH sensitivity, managing particle 
liposome size, and manipulating liposome-melting temperature by choosing different 
phospholipids with different transition temperature (table 1.3) (127, 130, 134). 
In addition, surface modification of liposomes with biocompatible polymers such as 
PEG has shown ptential as an effective method in achieving long-circulating liposomes (142, 
143). These biocompatible polymers are flexible and facilitate the formation protective 
impermeable layer around the liposome via surface grafting molecules (144, 145). However, 
the attachment of PEG polymers on the liposome surface has to be reversible to allow 
liposomal uptake by cells. Disassembly of PEG from liposome occurs by the effect of 
pathological factors as the liposome approaches the target cell by enhanced permeability and 
retention (EPR) (146). Polymers like poly[N-(2-hydroxypropyl) methacrylamide)], poly-N-
vinylpyrrolidones, and polyvinyl alcohol were also used for synthesizing long-circulating 
liposomes (147-149). 
Another method to create long-circulating liposomes is by altering liposome pH 
sensitivity. It can be achieved by creating novel lipid compositions, modifying liposome 
structure using pH-sensitive polymers, or combining both methods to extend liposomal t1/2 and 
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improve targeting. A pH-sensitive liposome with a PEG-modified surface is an example of 
long-circulating liposome that has efficient pH sensitivity allowing it to deliver and release 
ACs inside target cell (139). Also, liposomes composed of a pH-sensitive phospholipids, such 
as phosphatidylethanolamine (PE), were developed to release antisense oligonucleotides 
following liposomal degradation at acidic pH only (150). Further pH sensitive components for 
liposomal manipulation were discovered and discussed (151-153). Long-circulating liposomes 
have indicated enhanced bioavailability as discovered in several clinical studies (137, 154, 
155). 
Table 1.3. Examples of phospholipids used in liposome synthesis and their transition 
temperatures (127, 130, 134). 
 
Phospholipids Phase transition OC 
Dimyristoyl 
phosphatidylcholine 
(DMPC) 
23 
Dioleoyl 
phosphatidylcholine 
(DOPC) 
-22 
Distearoyl 
phosphatidylcholine 
(DSPC) 
55 
Dipalmitoyl 
phosphatidylethanolamine 
(DPPE) 
67 
Dipalmitoyl 
phosphatidylcholine 
(DPPC) 
41 
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1.5. Limitations of liposomes and hydrogels as carriers for 
controlled delivery system 
 Usually, liposomes are known to be safe and biocompatible, but in some cases like 
cationic liposomes they show some cytotoxicity specifically when administered in elevated 
doses (156). Furthermore, liposomes are difficult to sterilize since chemical agents may cause 
liposomal instability. Thus far, a filtration process using 220 nm membranes is the only 
recommended sterilizing method (130). Short shelf life and stability of liposomes are major 
concerns because of the difficulty with keeping liposomes stored for periods similar to other 
dosage forms. Liposomal stability is significantly influenced by chemical (oxidation or 
hydrolysis) and physical (aggregation or temperature) factors (157-159). Moreover, liposomes 
express very low encapsulation efficiency, which could affect the therapeutic efficacy if 
loaded AC does not meet required doses to be delivered. Although some studies discussed 
increasing liposomal encapsulation efficiency, hydrophobic ACs encapsulation remains less 
efficient compared to hydrophilic ACs (160-162).  
 Hydrogels as AC carriers have shown variable biocompatibility rates based on their 
polymeric monomers and cross-linkers compositions (163). Several disadvantages exist, such 
as reduced mechanical strength, where AC loading becomes less eficient (164). Also, rapid 
burst release of ACs from hydrogel matrices due to their high water content and moderately 
large network pores is a common issue (165). Similarly to liposomes, the sterilization process 
of hydrogels remains a challenge (34). 
 The above-mentioned drawbacks to liposomes and hydrogels as separate carriers are 
limiting their potentials to provide optimal controlled delivery of ACs, thus increasing the 
need to develop novel methods allowing these carriers to be improved for biomedical and 
pharmaceutical applications. Developing a system based on combining hydrogel with 
nanocarrier such as liposome could overcome some of the limitations associated with each 
system separately, especially those affecting the release rate. For instance, stability concern 
related to liposomes that lead to rapid release of ACs can be improved via embedding them 
into hydrogel (see below, 1.6). 
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1.6. Synergistic combination of nanocarriers with hydrogel as a 
novel controlled delivery system 
  Synergistic combination of different carriers as a novel controlled delivery system has 
attracted attention because of the capability for administrating several ACs while also 
controlling their release rate. Consequently, minimized side effects and improved therapeutic 
profiles can be achieved with lower dosage requirements (166-168). Systems that combine 
hydrogels cross-linking with either polymers or lipid based nanoparticles have been discussed 
in previous studies (169-171). For example, manipulating certain parameters icluding hydrogel 
polymer properties, concentration and composition of liposomes, as well as their interaction 
with hydrogels (e.g., swelling rate) can alter liposomes stuctural integrity and improve 
mechanical stability (172, 173). 
 
The loading process of any bioactive molecule either hormonal or synthetic therapeutic 
agents into hydrogel scaffolds, is accomplished through employing different chemical and 
physical binding factors (covalent bonding or electrostatic interaction) (174). In order to 
achieve improved spatial and temporal controlled release and delivery of ACs, manipulation 
of chemical and physical bindings within hydrogels is required (175). Still, the major concern 
about embedding bioactive compounds into hydrogels is the initial burst release or complete 
fast release of ACs. It is difficult to perfectly manage hydrogel network design completely 
with the developed synthetic methods so far, which in turn affects ACs release rate and 
efficacy (176, 177). To find a solutions to manage the burst effect and to improve ACs loading 
in hydrogel, two different nanoparticles of N-(2-hydroxyl) propyl-3-trimethyl ammonium 
chitosan chloride and carboxymethyl chitosan were mixed and embedded within a 
chitosan/poly(vinyl alcohol) hydrogel before gelation process. Propranolol (positively 
charged) and diclofenac sodium (negatively charged) were used as ACs. Controlling the 
release rate of ACs was obtained through altering the nanoparticles ratio embedded within the 
hydrogel (178).  
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To enhance AC controlled delivery, a recently developed technique uses two AC 
carriers of liposomes and hydrogels for topical administration (179). Cationic pH sensitive 
liposomes composed of L-phosphatidylcholine (PC) and 1,2-di-(9-Z-octadecenoyl)-3-
trimethyl ammonium propane (DOTAP) phospholipids were prepared and stabilized using 
gold nanoparticles. Then, the stabilized liposomes loaded with rhodamine B were embedded 
into polyacrylamide hydrogels at various cross-linking rates to investigate viscoelasticity 
effects over release kinetics. Results indicated that modifying cross-linking rate and the pH of 
the medium has a major effect not only on AC release, but also over the release of stabilized 
liposomes from hydrogel matrices (179).  
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1.7. Hypothesis and objectives 
Previously, hydrogels have been used as active compound delivery systems, but in 
some cases hydrogels suffer from rapid burst release of loaded active compounds. However, 
incorporating a secondary system such as liposomes could overcome the limitations of 
hydrogels in a synergistic manner since it could improve the stability of active compounds and 
their controlled release. Therefore, the main objective is to combine two active compound 
delivery systems in order to counteract deficiencies observed in the individual systems such 
that it would lead to an enhanced controlled release delivery system. More specifically, the 
goal is to develop a structured hydrogel with embedded liposomes loaded with active 
compounds that would be released in a controlled fashion.  
 
The first objective is to prepare and characterize three liposomal formulations using 
different concentrations of different components of phospholipids loaded with sulforhodamine 
B as the active compound. Following that, the effects of varying phospholipids ratios and 
thermal conditions on active compound release rate will be evaluated. 
 
The second objective is to synthesize and optimize hydrogels with a fixed cross-linking 
degree by a photopolymerization process using an acrylamide monomer, N, N’-methylene-
bis(acrylamide) cross-linker, and Irgacure® photoinitiator. Furthermore, three different 
controlled delivery systems based on three different liposomal formulations, each with a 
different phospholipid composition, embedded in a hydrogel loaded with sulforhodamine B 
prior to the gelation process will be developed. This will serve as a basis for studying the 
release rate of model active compound under different thermal conditions. Comparing results 
from both liposomes alone and liposomes embedded in hydrogels would indicate whether a 
combined system is capable of providing an extended release rate of active compounds.  
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2.1. Introduction 
Over the past two decades, significant advancements have occurred in the 
field of nanotechnology led to nano-scale particles whose physical and chemical 
properties are beneficial to therapeutic purposes (1). Most nanoparticle 
technologies involved in therapeutic applications have been found to be 
advantageous for controlled delivery systems of active compounds. Nanoparticles 
are made from either naturally sourced material or synthetic polymers. Natural sources 
are typically phospholipids, lipids, natural polymers such as chitosan, while as 
synthetic nanoparticles can be fabricated from polylactic acid (2), 
polycaprolactone (PCL), polylactic-co-glycolic acid (PLGA) or microgels 
(acrylate based polymers) (3-6). However, optimizing carriers for active 
compound delivery is a question of active compound use, encapsulation and 
release, shelf life stability, biocompatibility, biodistribution and functionality (7, 
8). In addition, when different materials used for developing carriers, possible 
side effects from residual materials after active compounds delivery that 
should be concerned. So, biodegradable nanocarriers with optimized half-life would 
be most practical for therapeutic use (9). 
The main goal of active compound encapsulation is to improve delivery to, or 
uptake by, target tissues or to minimize the toxicity of the free active compounds to 
non-target tissues (10). An improvement in either of the properties leads to an increase 
in therapeutic index, that is, the margin between the doses resulting in a 
therapeutic efficacy and toxicity to other tissues. Thus, developing a long-acting 
nanocarrier is of interest. Nevertheless, the criteria for choosing the appropriate 
nanocarrier most frequently depends on the active compound’s potency, stability, 
solubility, charge, and molecular weight. Generally, finely designed nanocarriers, such 
as liposomes, are able to encapsulate only a small amount of active compound 
molecules. Mainly, high potency active compounds are usually encapsulated in 
practice (11). Since Alec Bangham discovered liposomes 40 years ago, they have 
gained an interest and have been involved in medical and pharmaceutical 
research as a fundamental tool in controlled active compound delivery systems 
(12). Another type of nanocarrier that has 
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recently attracted attention as an efficient polymeric based drug delivery system is 
nanogels. They have demonstrated flexibility in their capacity for both active 
compounds encapsulation and release. As such, there is a room to improve the 
encapsulation rate of a variety of active compounds (13). Nanogels can be modified to 
respond to environmental changes to facilitate spatial and temporal controlled release in 
physiological conditions (14). In this study, we have employed chitosan-based nanogels 
because of their bioactivity, biodegradability and biocompatibility properties that make 
them optimal for in vivo applications (15). Chitosan is a natural polyelectrolyte, β 
(1→4)-linked linear copolymer of 2-amino-2-deoxy-β-d-glucan (GlcN) and 2-
acetamido-2-deoxy-β-d-glucan (GlcNAte). Conformation and resulting characteristics 
of chitosan rely on different physicochemical parameters (16-20). Also, chitosan was 
found to be advantageous in terms of active compounds delivery and regenerative 
medicine (21, 22). 
The thermo-sensitivity and pH sensitivity of nanocarriers could be manipulated to 
control the release, or trigger the release, of active compounds (23-25). NIPAM microgels 
were first reported by Pelton and Chibante in 1986 (26). Microgels can be made from N-
isopropylacrylamide (NIPAM) where pNIPAM is a thermo-sensitive polymer that can be co-
polymerized with a charged monomer to provide pH-sensitivity. The authors polymerized 
NIPAM with N,N’-methylene-bis(acrylamide) (bisAc) in water to produce micro-scaled 
latexes sensitive to temperature. These particles have the capability to swell below the lower 
critical solubility temperature (LCST) of NIPAM, at approximately 32°C, while it is capable 
of collapsing and decreasing their sizes above the LCST (27). Since then, this effect has been 
widely characterized and it was found possible to finely tune the LCST and electrical charge 
of the microgels to adequately respond to pH or temperature changes in specified range (28). 
Furthermore, electrical charges within the polymer structure might enhance the encapsulation 
of a drug within the microgel as well as control its release through electrostatic interaction 
between the microgel and a charged active compound. No organic solvents are used for the 
synthesis; it is produced in one scalable step synthesis and the size, size variation, surface 
properties and monomer composition can be modified to adjust the microgel for specific 
therapeutic applications (29, 30). 
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Invasive administration methods would benefit from sustained release, which could 
reduce dosage frequency. For example, implants, drug loaded patches and tissue design 
platforms are potential applications but require a biocompatible polymeric matrix to entrap 
nanocarriers capable of sustaining and controlling the release of the active compounds (31, 
32).  
Synergistic combination of different carriers as a novel controlled delivery system has 
attracted attention due to its potential for administrating different active compounds	while also 
providing better controlled release rate. Consequently, minimized side effects and improved 
therapeutic profiles can be achieved with lower dosage requirements (33). Synergistic 
controlled delivery systems are currently fabricated with hydrogel embedding either polymers 
or lipid based nanoparticles (9, 33-35). 
 A hydrogel with high water content was designed to represent biocompatible or 
tissue mimicking synthetic matrices for embedding nanocarriers. We have evaluated 
the capabilities of liposomes, nanogels, and microgels nanocarriers embedded in 
acrylamide/bisAc polymeric matrix as a generic matrix. The objective is to evaluate the 
potential in controlling the release of a model active compound from a three-
dimensional matrix embedding different nanocarriers separately and evaluating the 
impact of temperature, medium salinity and composition of each nanocarrier. In this 
study, the comparison between three different nanocarriers embedded within a hydrogel 
should help elucidate the different release mechanisms and how the structure influences 
the release behaviour of each formulation. 
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2.2. Materials and methods 
2.2.1. Chemicals and reagents 
Phospholipids including 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 
1,2-dihexadecanoyl-sn-glycero-3-phosphocholine (DPPC) were purchased from Avanti 
Polar Lipids (USA) and used without further purification. For liposome preparation, 
Kiton Red S (Sulforhodamine B) was purchased from Alfa Aesar (Ward Hill, MA, 
USA). Surfactant triton X-100 provided by Sigma–Aldrich was used for the release 
kinetics measurement. Sephadex G-50 from Sigma was used to separate liposomes 
from non-encapsulated sulforhodamine B solution. For nanogels preparation, chitosan 
(Mw= 88 kDa) derived from shrimp shells was purchased from Sigma (France). 
Hyaluronic acid sodium salt (Mw = 1 400 kDa) was extracted from Streptococcus equi 
subspecies (Sigma-Aldrich, France) and used as received. Sodium tripolyphosphate 
(TPP) was purchased from Alfa Aesar (Ward Hill, MA, USA). Citric acid was 
purchased from Anachemia (Canada). The microgel was prepared from N-
Isopropylacrylamide (NIPAM), N,N’-methylene-bis(acrylamide) (BisAc), methacrylic 
acid (12) and sodium dodecyl sulfate (SDS) which were provided by Sigma-Aldrich 
(Canada). Ammonium persulfate initiator was provided by Fisher-Biotech (Canada). To 
prepare the hydrogel, Acrylamide (AAm) monomer and N,N’-methylene-
bis(acrylamide) (BisAc) cross-linker were purchased from Sigma-Aldrich (Canada) and 
Irgacure ® 2959 as photoinitiatior was supplied by BASF (Switzerland). HEPES buffer 
from Sigma–Aldrich was used for hydrogel preparation and analysis 
 
2.2.2. Preparation of formulations 
2.2.2.1. Liposome preparation 
The preparation of liposome was started by dissolving of 20 mg of a 
(DOPC:DPPC) mixture at the required ratio	in 1 mL of chloroform in order to prepare 
three different batches with phospholipids molar ratios of (50:50), (60:40), and (70:30) 
of DOPC:DPPC. Then, the solvent was slowly removed by rotary evaporation under 
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reduced pressure at 50°C to form a thin lipid film in a 10 mL round bottom flask. The 
lipid film was further dried by freeze-drying for 15 minutes to eliminate the residual 
solvent content. 1 mL of 30 mM sulforhodamine B in a buffer of 5 mM HEPES and 
145 mM NaCl was added to the flask to hydrate the lipid film. This process was 
performed at 60°C while mixing and vortexing for 20 minutes until all the 
phospholipids were hydrated and removed from the flask wall. The dispersion was then 
treated by 10 freeze-thaw cycles followed by 21 cycles of extrusion (Avanti Mini-
Extruder; Avanti Polar Lipids, USA) through a polycarbonate membrane with a pore 
size of 200 nm and by the same process in a 100 nm membrane in order to approach 
small monodisperse unilamellar liposomes. Non-encapsulated sulforhodamine B was 
separated from liposomes by size exclusion chromatography using 1 x 20 cm Sephadex 
G-50 (medium) column equilibrated in a pH 7.4 buffer (5 mM HEPES and 145 mM 
NaCl). After that, purified liposomes with final total volume of ~ 3 mL were collected 
and stored in darkness at 4°C in 4 mL glass vials for later tests. 
 
2.2.2.2. Chitosan nanogel preparation and drug loading 
 For the nanogel, chitosan (CS) and hyaluronic acid (HA) were chosen as polymeric 
matrix for biocompatibility reasons. The cationic character of chitosan in acidic solution 
allows electrostatic interactions with negatively charged small molecules or polymers to form 
nanoparticulate complexes through ionic gelation (36). CS was solubilized in 9 mL of 10 % 
(w/v) citric acid aqueous solution at concentration of 2.5 mg/mL under magnetic stirring for 
45 minutes until full dissolution. Next, the CS solution was filtered using a 0.2 µm nylon 
membrane filter (Ultident Scientific, Canada). A solution of TPP 1.2 mg/mL and HA 0.8 
mg/mL was prepared in 4.5 mL milli-Q water under magnetic stirring until full dissolution. 
The solution was also filtered by 0.2 µm nylon membrane filter as same as in CS. 
 
 Sulforhodamine B at a concentration of 4 mg/mL was then added to the TPP/HA 
solution under magnetic stirring for 15 minutes. Chitosan-based nanogels were formed 
spontaneously during dropwise addition of 4.5 mL of the TPP / HA solution to 9 mL of CS 
solution under ultrasonication (Fischer Scientific Sonic Dismembrator F550 Ultrasonic 
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Homogenizer; power sonicator 20%) on an ice bath for 90 seconds. The formation of inter- 
and intramolecular electrostatic-mediated cross-linking among polyanions and protonated CS 
chains induced the gelation process (35). Once the dropwise addition was finished, continuous 
magnetic stirring was maintained for 20 minutes. The resulting loaded nanogels were stored at 
4°C and protected from light exposure. A volume of 12 mL of loaded nanogel suspensions 
were purified three times at room temperature using 1.2 L of 5 mM HEPES buffer by 
tangential flow filtration using MicroKros® hollow fiber modules (Spectrum, MicroKros® 
ME, MWCO 0.05 µm) in order to remove citric salts and the non-encapsulated 
sulforhodamine B. 
 
2.2.2.3. NIPAM-co-MAA microgel preparation 
Thermosensitive microgels were prepared in order to include anionic charges at 
different concentrations (provided by MAA co-monomer) within the NIPAM structure. 
The synthesis of the NIPAM-co-MAA particles was carried out in a single step.  
NIPAM and MAA were dissolved in degassed milliQ water at different molar ratios 
(molMAA / [molNIPAM + molMAA]) (30, 37-39). NIPAM and MAA were dissolved 
in degassed milliQ water at different molar ratios (molMAA / [molNIPAM + 
molMAA]), (table 2.1). BisAc at 5% molar ratio of total monomers and cross-linker in 
the particle and SDS at 867 µmol/L were added to the degassed solution. The contents 
were stirred until complete homogenization. A total of 150 mL of monomer/cross-
linker/surfactant solution was transferred into a three necked flask heated under reflux 
at approximately 60oC with constant Argon gas flow and mechanical stirring (275 
rpm). The reaction was initiated with the addition of 10 mL APS (solution at 2.9 
mmol/L) degassed by vacuum, while slowly increasing temperature to 75°C, 
maintaining steady Argon flow rate and mechanical stirring speed. The reaction was 
stopped after 4.5 hours by cooling down the particle suspension and removing large 
aggregates if any. The microgels were purified in batches of 60-70 mL by two 
consecutive dynamic dialysis in 20 L milliQ water for 16 hours and 4 hours 
respectively, using Spectra/Por® Tube-A-Lyzer® (Rancho Dominguez, USA) a 
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dynamic dialysis device with 100 kD MWCO cellulose ester membrane. Microgel 
suspensions were stored at 4°C until use. 
 
2.2.2.4. Hydrogel preparation 
Hydrogels were prepared by free radical photopolymerization of acrylamide 
(AAm) as the monomer, and N-N’-methylene-bisacrylamide (BisAc) as a cross-linker 
in HEPES buffer (pH 7.4) with cross-linker:monomer molar ratio of (5% w/v) (40). 
The cross-linker/monomer solution was prepared by dissolution of 1.90 g of AAm and 
100 mg BisAc in 20 mL of 5 mM HEPES and 145 mM NaCl under magnetic stirring. 
This stock solution was frozen at – 80°C for 1 hour. Before the polymerization process, 
the cross-linker/monomer solution was degassed using a vacuum pump for 30 minutes 
to eliminate dissolved oxygen that would otherwise prevent free radical 
photopolymerization. Following that, the solution was incubated in a water bath at 
32°C for 20 minutes. 2 mL of the solution was then collected into 10 mL glass beaker 
where the photopolymerization process takes place. 
 
  A solution of photoinitiator was added to an initiator/total monomer molar ratio of 5% 
in the final gel in order to start the reaction. Under magnetic stirring, the initiator solution was 
prepared by dissolving 5.8 mg of Irgacure® 2959 in 2 mL of HEPES buffer that had been 
already frozen, degassed and thawed. 300 µL of initiator solution were added to the reaction 
mixture within the beaker. Liposomes were introduced into the hydrogels by diluting purified 
liposome suspensions in the reactive medium of hydrogel synthesis. 
 
 For hydrogel preparation embeded with R6G-loaded microgels, each hydrogel was 
prepared separately. 190 mg AAm and 10 mg BisAc were dissolved in R6G-loaded microgel 
suspension (volume determined by drug loading) and the volume was adjusted with HEPES 5 
mM without salt or milliQ water (depending on R6G loading medium) to reach the same AAm 
/BisAc concentration prior to the addition of Irgacure® 2959.  
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The photocrosslinked hydrogels were obtained by exposing the 10 ml beaker 
containing the mixture to a UV lamp (365 nm; High Intensity UV Lamp; 40 min 
exposure). The beaker was covered with a glass slide to prevent evaporation. After 
photopolymerization, hydrogels of 5 mm diameter and thickness of ~ 5 mm disks were 
cut out using a biopsy punch (Miltex ®) for release study. 
 
2.2.3. Physicochemical characterization of formulations 
 The size of liposomes and nanogels were measured using dynamic light scattering (DLS) 
from a Malvern Zetasizer NanoZS (Malvern Instruments, UK), which were calculated from 
the Z-averages of the hydrodynamic diameters (dH, Z) and polydispersity indexes (PdI). Each 
sample was analysed in triplicate at 25°C. Water and water-citric acid (0.48 M) mixtures were 
used as reference dispersing media for liposomes and nanogels respectively. The size of each 
microgel suspension was determined as a function of temperature to characterize its thermo-
sensitivity. Measurement started from 20°C, with 2°C increments between each measurement, 
up to 40°C in milliQ water, phosphate buffed saline at pH 7.4 (PBS) and HEPES 5mM 
without salts at pH 7.4. Zeta potential data were measured by electrophoretic light scattering 
(ELS) at 25°C, 150 V, in triplicate for each sample (Malvern Zetasier Nano-ZS) in MilliQ 
water for liposomes and nanogels. The microgel zeta potentials were measured in 4 mM NaCl 
medium at 22°C and 38°C.  
 
2.2.4. Determination of loading efficiency (LE%) and drug loading (DL%) 
2.2.4.1. Liposome 
In order to determine the DL% for each liposome formulation, the Bartlett 
method was performed for each formulation following their purification to quantify 
inorganic phosphate in phospholipids, which will be used to calculate the recovered 
concentration of liposome phospholipids (41). Then, certain volume was collected into 
quartz cuvette from each formulation dispersed in 5 mM HEPES and 145 mM NaCl 
buffer (pH 7.4) with final volume of 3000 µl containing fixed concentration of 
liposomes of 15 µM loaded with sulforhodamine B. The amount of loaded 
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sulforhodamine B in the liposomes was determined by spectrofluorimetry (Hitachi F-
2710 fluorescence spectrophotometer) after addition of 10 µl of Triton X-100 while 
heating at 65°C and stirring for 10 minutes, resulting in liposomes permeation and 
release their content totally until no further increase in intensity was noticed. Then, 100 
µL of suspension was collected and further diluted 10 times in 5 mM HEPES and 145 
mM NaCl to fit a linear concentration range. Sulforhodamine B intensity was measured 
under stirring at maximum emission wavelength of 582 nm after excitation of samples 
at 563 nm. The excitation and emission slits were fixed at 5 nm for all measurements. 
Fluorescence intensity of diluted sulforhodamine B from each formulation was found to 
be linearly proportional to sulforhodamine B concentrations ranging from 0.005 µM to 
1µM. After that, the total quantity (adjusted for dilution factor) of sulforhodamine B 
released was calculated based on the concentration obtained from the calibration curve. 
The quantities of loaded sulforhodamine B in the stock formulations were also 
calculated. Following that, sulforhodamine B loading efficiency (LE%) and drug 
loading (DL%) of liposomes were calculated as: 
 𝐿𝐸%= !!"#!"#$%$!"#$!"!#$ ×100                        (Eq. 2.1) 
 𝐷𝐿%= !"#$!"#$%$!!" ×100                               (Eq. 2.2) 
 𝐷𝑟𝑢𝑔!"#$%$ is the amount of model drug loaded in nanoparticles, 𝐷𝑟𝑢𝑔!"!#$ is the 
total amount of model drug used in the preparation, and 𝑀!" is the total mass of 
obtained nanoparticles for every formulation.  
 
2.2.4.2. Nanogels  
Following the preparation of sulforhodamine B loaded nanogels, 500 µL from 
the batch was collected and centrifuged at 20000 rpm for 20 minutes in order to 
separate nanogels from the aqueous suspension. Then, 100 µL of the supernatant was 
collected and diluted 100 times in 5 mM HEPES buffer to fit the calibration curve. The 
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amount of free sulforhodamine in the supernatant (djusted for dilution factor) was 
determined by a spectrofluorimetry (Tecan Safire Monochromatic Fluorescence). The 
sulforhodamine B intensity was measured at maximum emission wavelength of 582 nm 
after excitation of samples at 563 nm. The excitation and emission slits were fixed at 5 
nm. Fluorescence intensity of diluted supernatant was found to be linearly proportional 
to sulforhodamine B concentrations ranging from 0.005 µM to 1µM. The 
sulforhodamine B loading efficiency (LE%) and drug loading (DL%) of nanogels were 
calculated using Eq. 2.1 and Eq. 2.2. 
 
2.2.4.3. NIPAM-co-MAA microgels  
 Microgel concentration in the stock solution was determined by freeze-drying after 
purification, and then weighting the residual polymer in triplicate. A fluffy white powder 
remains in the tubes allowing for easy mass measurement. Microgel suspensions were loaded 
using R6G positively charged fluorescent dye. Since microgels of NIPAM-co-MAA are 
negatively charged, drug loading ocurred through electrostatic interaction. A stock solution of 
0.5 mg/mL R6G was prepared in milliQ water and kept at 4°C until use. The stock microgel 
suspension was diluted in milliQ water to reach a concentration of 0.5 mg/mL. 100 µL of 
diluted microgels were transferred, and different concentrations of R6G were used to load the 
microgels (0.2, 0.4, 0.6, 0.8 mg/mL) and topped with milliQ water to 500 µL. HEPES 5 mM 
with 145 mM NaCl (pH 7.4) and HEPES 5 mM (pH 7.4) without salt were used for 
calculating drug loading and loading efficiency. The suspension was vortexed and then 
incubated for 1 hour at different temperatures 25°C and 40°C. Temperature cycling was tested 
in order to verify if swelling / shrinking cycles could improve R6G loading. The sample 
started incubation in the swollen state at 0°C or 25°C for 20 minutes then was heated to 40°C 
for 20 minutes then returned to the initial temperature for the last 20 minutes. At the end of the 
incubation process, the drug-loaded microgels were centrifuged at 25000 G for 30 minutes. 
The supernatant was collected, then diluted 20 times and transferred to a 96-well plate for 
fluorescence measurement. Fluorescence of the diluted supernatant was determined by 
spectrofluorimetry (Tecan Safire Monochromatic Fluorescence) and concentration was 
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determined using a linear calibration curve between 10 and 0.25 µg/mL. Each parameter in 
this study was assessed in triplicate and measured independently three times (n= 3). DL% and 
LE% were calculated using Eq. 2.1 and Eq. 2.2. 
2.2.4.4. Drug loading for drug release using NIPAM-co-MAA microgels  
 In order to obtain a sufficient quantity of loaded R6G, the loading volume for each 
microgel suspension was 90 mL using milliQ water. A total of 30 mL was used for 10, 12.5, 
15, 20% MAA and 90 mL was used for 5% MAA in HEPES 5 mM without a salt medium. 
R6G concentration was set to 0.06 mg/mL and the microgel concentration was set to 0.1 
mg/mL. The suspension was then incubated at 25°C for 1 hour. Two cycles of centrifugation 
and re-suspension of the microgels were performed to remove free R6G. Centrifugation was 
carried out at 30000 G for 1 hour at 4°C using  Sorvall RC-6 (Thermo-Scientific) and Rotor 
SS-34 centrifuges. Re-suspension occurred in the same volume and incubation medium. 1 mL 
of milliQ water or HEPES 5mM without salt was used to re-suspend the remaining microgel at 
the end of the centrifugation process. To evaluate the concentration of encapsulated R6G, 20 
µL was collected from the suspension and was diluted 200 times in HEPES buffer (containing 
salt). DL% and LE% were calculated using Eq. 2.1 and Eq. 2.2. The concentration of 
microgels was determined after freeze-drying. 
 
2.2.5. Release study from liposomes 
 Release from suspended liposomes was performed as a function of liposomal 
concentration, composition and temperature. The release profile of sulforhodamine B from 
liposomes was measured and evaluated by conventional fluorescence for three different 
formulations (50:50, 60:40, and 70:30) separately over 72 hours at 4°C and 37°C. 
Sulforhodamine B intensity was measured using a spectrophotometer (Hitachi F-2710 
fluorescence spectrophotometer) while stirring at the maximum emission wavelength of 582 
nm and excitation wavelength of 563 nm. The excitation and emission slits were fixed at 5 nm 
for all measurements.  
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Two samples were collected from the stock of every loaded liposome formulation and 
dispersed separately in 5 mM HEPES and 145 mM NaCl (pH 7.4) up to a final volume of 
3000 µL and total liposomes concentration of 15 µM. After mixing and pouring into 20 ml 
glass vials, one set from each formulation was stored under darkness at 4°C while the other set 
was incubated under darkness at 37°C. The samples for each formulation (50:50, 60:40, and 
70:30) incubated at 4°C and 37°C were separately collected into quartz cuvettes, where 
fluorescence intensities were measured while stirring at regular time intervals over 72 hours. 
To obtain maximum sulforhodamine B release and intensity, 10 µL of Triton X-100 was 
added and stirred for 10 minutes while heating at 65°C. resulting in liposomes permeation and 
release their content totally. 
 Based on calibration curve between 0.024 µM and 4.8 µM, fluorescence intensities of 
released sulforhodamine B during different time intervals and after obtaining the maximum 
release (using Triton X-100) were used to calculate the released concentrations. The release 
percentage was calculated from the concentrations of sulforhodamine B released during time 
intervals and maximum released concentrations of sulforhodamine B after liposomes 
permeation. 
 
2.2.6. Release study from hydrogel 
 During hydrogel synthesis, the loaded liposomes were added to the reactive mixture of 
hydrogels. The photopolymerization process yielded hydrogels with embedded liposomes 
loaded with 0.27 mg of sulforhodamine B. Then, hydrogels were cut into 5 mm diameter and 
thickness cylinders and their masses were measured in order to estimate the sulforhodamine B 
mass content in every cylinder, assuming that the solution mixture is homogenous. The same 
process was repeated for nanogels. Hydrogel discs 5 mm diameter and thickness of 5 mm were 
separately placed in 10 mL of 5 mM HEPES buffer (pH 7.4) at 4°C and 37°C. After that, at 
different time intervals, 200 µL of the supernatant was taken (and replaced by 200 µL of fresh 
HEPES buffer) and analysed by spectrofluorimetry (Tecan Safire Monochromatic 
Fluorescence). The release study was performed in triplicate (n= 3) over 240 hours for 
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liposomes and 72 hours for nanogels respectively. The percentage of released sulforhodamine 
B was calculated relative to the estimation of the maximum sulforhodamine B concentration 
that could be released. Release studies using microgels embedded in hydrogels was performed 
using R6G instead of sulforhodamine B. From the medium, 300 µL was collected and 
replaced by the same volume with fresh HEPES buffer. R6G released from the microgel 
embedded in AAm/BisAc was investigated over 72 hours. 
 
2.3. Results and Discussions 
2.3.1. Preparation and characterization of liposomes 
 Three formulations with different phospholipids molar ratios (50:50, 60:40, and 70:30) 
were prepared in order to identify the effect of liposome concentration over particle size and 
zeta potential (table 2.1). Increasing DOPC concentration in the liposome had a limited effect 
on changing the hydrodynamic diameters among all formulations with a stable PDI value of 
0.1. However, ZP values were found to increase significantly from -24.03±4 mV in 50:50 
formulation to -60.7±1.6 mV along with the increase in DOPC. Results (table 2.1) showed that 
the highest DL (40%) and LE (8%) were obtained in the formulation containing equal ratios of 
DOPC:DPPC, while the lowest DL (12%) and LE (1%) were obtained from the DOPC:DPPC 
(70:30) formulation. These findings suggest that 50:50 formulation is best to achieve optimal 
sulforhodamine B loaded liposomes because of higher encapsulation rates associated with 
higher DPPC content, which prevents loaded molecules from leaking out. The variations in 
DL and LE are due to the change in the liposome membrane fluidity, which depends on 
differences in both the phospholipid composition and temperature. Since DOPC and DPPC 
have transition temperatures of -21°C and 41°C, representing mobile phase and solid phase 
respectively and due to presence of double bonds in the DPOC acyl chain, the increase in the 
DOPC:DPPC provided liposomes with higher bilayers membrane fluidity. As a result, the 
liposomes with higher DOPC composition (60:40, 70:30) were not capable of encapsulating 
the same amount of sulforhodamine B compared to liposomes with higher DPPC (50:50). 
Also, the ZP values tend to be lower in the formulations with higher DOPC composition. 
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* Loading efficiencies and drug loading for microgels are given by loading in milliQ water and HEPES 
5mM respectively (water –HEPES). Microgel particle size was measured at 26°C, while zeta potential 
was measured at 22°C. 
 
 
 
 
 
 
 
 
 
Table 2.1. Composition, physicochemical properties and loading characterization of formulations. 
Formulation 
design Composition 
Particle 
Size, PS 
(nm) 
Polydispersity 
Index, PDI 
(a.u) 
Zeta 
Potential, ZP 
(mV) 
Loading 
Efficiency, 
LE 
(%) 
Drug 
Loading, DL 
(%) 
Drug model 
Liposome DOPC:DPPC 
50:50 
132 ± 2 0.100 -24.0 ± 4.0 8 40 Sulforhodamine B 
(SRB) 
DOPC:DPPC 
60:40 
140 ± 1 0.100 -57.7 ± 1.7 5 27 
DOPC:DPPC 
70:30 
 
133 ± 1 0.070 -60.7 ± 1.6 1 12 
   Nanogel HA + 
Chitosan 
195 ± 0 0.020 +46.3 ± 2.6 96 35 
 
 
Microgel* 
 
 
NIPAM 
 
203 ± 2 
 
0.049 
 
-1.8 ± 0.1 
 
0.7 – N.D. 
 
0.4 - N.D. 
 
Rhodamine 6G 
(R6G) NIPAM-co-
MAA 5% 290 ± 4 0.077 -6.3 ± 0.1 1.3 – 3.5 0.8 – 2.1 
NIPAM-co-
MAA 10% 356 ± 4 0.036 -7.0 ± 0.2 10.4 – 38.3 5.9 – 18.7 
NIPAM-co-
MAA 12.5% 496 ± 2 0.123 -7.2 ± 0.3 8.5 – 44.7 4.9 – 21.2 
NIPAM-co-
MAA 15% 501 ± 10 0.121 -8.9 ± 0.1 13.9 – 49.3 7.7 – 22.8 
NIPAM-co-
MAA 20% 512 ± 15 0.080 -10.5 ± 0.4 14.6 – 50.6 8.1 – 23.3 
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2.3.2. In vitro release from liposomes 
 The release profile of sulforhodamine B from the liposomes for the three different 
formulations that were investigated in 5 mM HEPES and 145 mM NaCl buffer (pH 7.4) at 4°C 
and 37°C (figure 2.1). As seen in figure 2.1A, the release of sulforhodamine B from all 
formulations is controlled by two main factors: liposomes composition and the local 
temperature where the release takes place. 
 
 The 50:50 formulation showed significant stability and slow release rate with no burst 
release at both temperatures due to higher DPPC content in comparison to the other 
formulations. At 4°C about 41% of liposomes content was released after 72 hours, while 66% 
was released following 72 hours of incubation at 37°C. The difference in release rates between 
the two temperatures suggests a significant sensitivity to temperature. 
  
 Increase in DOPC concentration in the 60:40 formulation led to an initial burst release 
and an increase in release rate from liposomes at both temperatures. After 72 hours of release, 
almost 67% and 78.1% of sulforhodamine B had been released at 4°C and 37°C, respectively. 
The temperature sensitivity of the 60:40 formulation was noticeably lower than 50:50 
formulation (figure 2.1A).  
 
 Similarly, sulforhodamine B release behavior presented stronger burst release in the 
70:30 formulation compared to that of 60:40 due to higher DOPC content within liposomes 
structure. Typically, further addition of DOPC in liposomes resulted in depleting about 38% of 
sulforhodamine B at 4°C and 46% at 37°C within three hours. All loaded sulforhodamine B 
was released after 24 hours in all cases. 
 
  An additional test was performed on the 60:40 formulation by exposing the liposomes 
to UV light for 15 minutes. The purpose of this test was to identify whether UV light and its 
thermal energy would affect liposome structural integrity and consequently the 
sulforhodamine B release rate from liposomes during hydrogel preparations or not. As 
illustrated in figure 2.1B, sulforhodamine B release was studied by spectrofluorimetry for 
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1000 seconds (with a registered fluorescence intensity of 15.75 at t= 0 seconds, and 20.33 at t= 
1000 seconds). Following 15 minutes of exposure, it had been found that the release rate was 
moderately changed (68.47 at t=0 seconds, compared to 79.37 at t=1000 seconds). Such 
increase in the fluorescence intensity of sulforhodamine B can be due to a thermal heating 
during UV exposure, which could enhance sulforhodamine B release as a result of liposome 
permeation. Since DOPC represents 60% of the liposomes composition which could altered by 
higher temperature and affect liposomes structural uniformity. An alternative explanation 
could be that possible oxidation of the double bonds in DOPC could disrupt the liposomes 
stability. 
 
 
 
Figure 2.1. Release behaviour of sulforhodamine B from liposomes. (a) Sulforhodamine B 
release during 72 hours from three different formulations of liposomes at 4 °C and 37 °C. (b) 
Impact of UV light on sulforhodamine B release during 1000 seconds from (60:40) 
formulation before and after 15 minutes of exposure. 
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2.3.3. In vitro release from hydrogel vs. Hydrogel embedding liposomes  
The release behaviour of sulforhodamine B from hydrogel only and from liposomes 
embedded in hydrogels in 5 mM HEPES and 145 mM NaCl buffer (pH 7.4) at 4°C and 37°C 
for 240 hours is described in figure 2.2. 
 
The free form of sulforhodamine B loaded within the hydrogel without using 
liposomes has shown very rapid release rate in comparison to liposomes incorporation. Most 
of the sulforhodamine B content within the hydrogels were released within 24 hours. 
However,  incorporation of liposomes into hydrogels provided a slower and controlled release 
of sulforhodamine B for all liposome formulations. In the 50:50 formulation, UV light 
exposure could have been responsible for the initial burst release observed at both 
temperatures in contrast to the release from liposomes alone before embedding into hydrogels. 
At 4°C, the cumulative release of sulforhodamine B started at t= 24 hours with 30.37±2.76% 
of total sulforhodamine B and was slow until t=144 hours when the release increased to a 
cumulative release of 40.04±2.87%. At t= 240 hours, only 52.36±2.38% of the total quantity 
of sulforhodamine B loaded within the hydrogel was released. Correspondingly, the 50:50 
formulation has shown significant sensitivity to increases in temperature, as revealed by the 
change of the cumulative release behaviour compared to 4°C. After 24 hours of incubation at 
37°C, 49.84±1.03% of sulforhodamine B was diffused from the hydrogel and continued to 
diffuse until 79.22±4.66% was released after t= 240 hours. 
 
The release behaviour from hydrogels for the 60:40 formulation was also extended 
until t= 240 hours with superior control compared to liposomes alone. Also, it was observed 
that significant burst release followed by steady increased release rate every 24 hours at both 
temperatures. As the DOPC concentration increased in this formulation, the release rate 
increased slightly in physiological conditions (97.46±3.61% after t= 240 hours) compared to 
the release at 4°C 86.18±3.24% after t= 240 hours. 
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The release from hydrogels embedded with the loaded 70:30 formulation was very 
rapid but still slower than the release of free sulforhodamine B from the hydrogels due to the 
same factors as in the 60:40 formulation, The hydrogels had released all the free 
sulforhodamine B after t= 24 hours, while in case of 70:30 the release was completed after t= 
48 hours at both 4°C and 37°C. 
 
In order to verify whether intact liposomes have been released from the hydrogels, 10 
µL of 1% of octaethylene glycol monododecyl ether (C12E9, purchased from Sigma) 
detergent were added to the collected supernatants. Results showed an increase in the 
fluorescence intensity in each sample collected, suggesting that the collected supernatants 
contained not only free sulforhodamine B, but also liposomes loaded with sulforhodamine B 
as well (figure 2.2B). Liposomes are released from the hydrogel shortly after incubation was 
started which suggests that they were located close to hydrogel interface (figure 2.2B). Figure 
2.3 depicts this release mechanism. 
 
 
Figure 2.2. Release behavior of sulforhodamine B from hydrogel embedded with liposomes. 
(a) Sulforhodamine B release after 250 hours from hydrogel embedded with three different 
formulations of liposomes at 4 °C and 37 °C. (b) An increase in sulforhodamine B release rate 
from the 60:40 formulation following addition of 1% C12E9 surfactant suggesting liposomes 
escape from the hydrogel at 4 °C and 37 °C for over 250 hours. 
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Figure 2.3. Proposed release mechanism of liposomes and sulforhodamine B from hydrogels 
at different time intervals. 
 
2.3.4. Chitosan nanogels characterization 
The chitosan and HA nanogel formulation loaded with surforhodamine B was initially 
characterized in terms of particle size (42) and zeta potential (ZP) (table 2.1). The particle size 
showed narrow distribution (PDI = 0.02) and small nanoparticles. The zeta potential indicates 
a cationic charge (ZP = 46.3 ± 2.6 mV) on the surface of the nanogel and provides insights 
about its structure. Interestingly, the nanogels seem structured in a way that TPP is 
interpenetrated within the chains of HA in the core of the nanogel, and chitosan at the 
periphery of the nanogel, exposing its positive charge. 
 
 DL and LE of sulforhodamine B were also evaluated in nanogels by centrifugation. 
High loading efficiency was achieved (LE= 96%) and consequently achieving high drug 
loading (DL= 35%) of sulforhodamine B. The chitosan-dense outer shell suggested by ZP data 
might have facilitated the encapsulation or complexation of surlforhodamine B which carries a 
net negative charge to the nanogel surface. While keeping its zwitterionic nature at loading 
pH, it could also have yielded to some interaction with anionic HA or TPP chains, resulting in 
such high loading.  
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2.3.5. NIPAM-co-MAA microgels characterization 
 We have synthesized multiple microgels using NIPAM as a reference structure in 
which we have added different ratios of MAA, ranging from 5% to 20%. Particle size (42) and 
ZP were measured separately after purification of the microgel suspensions at 26°C and 22°C 
respectively (table 2.1). At 26°C, results showed that PS increased with increasing MAA 
content from 203 nm (MAA 0%) to 512 nm (MAA 20%) and PDI remained below 0.15 for 
each formulation indicating narrow distribution in milliQ water. ZP decreased with increasing 
MAA ratios from -6.3 ± 0.1 mV (MAA 5%) up to -10.5 ± 0.4 mV (MAA 20%), while NIPAM 
without MAA remained mostly neutral (ZP = -1.8 ± 0.1 mV) at 22°C (table 2.1). 
 
 Thermo-sensitivity of microgels was also investigated. Particle size was determined 
from 20°C to 40°C by 2°C increments. The microgels exhibited an increase in collapse 
temperature by increasing MAA content from 33°C (MAA 0%) to 36°C (MAA 20%) as 
already reported (43). Collapsed state (T > LCST) was characterized by an approximated 50% 
PS reduction compared to the swollen state (T < LCST). Interestingly, for MAA ratios higher 
than 12.5%, a second collapsed state was observed between temperatures 22°C to 26°C (figure 
S2.1). This observation suggests that MAA distribution in the microgel particle is not 
homogeneous at such high content leading to richer domains exhibiting different thermal 
properties. Due to the fact that PS and PDI are similar to those found at low MAA content, it 
is unlikely that the appearance on this second thermal transition is due to a distinct population 
of microgel particles formed during the synthesis. 
 
Since all microgels are kept and mostly were used in milliQ water, the effect of the 
suspension medium on the size of the microgels and on its thermosensitivity was investigated. 
Compared to milliQ water, microgels in saline solution (Phosphate 10mM + 145 mM NaCl) 
without MAA started to aggregate at 32°C (figure S2.1) where it usually starts to collapse (T > 
LCST). In this case the salt is the major cause of aggregation since, as reported by many 
studies, the salt reduced electrostatic repulsion of each particles causing them to aggregate. 
Interestingly, such aggregation was not observed with NIPAM-co-MAA microgels, suggesting 
that the 5% MAA content was sufficient to keep colloidal stability in simulated physiological 
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conditions. However, a reduced thermosensitivity of microgels was observed in PBS (table 
2.2). The increased pH compared to milliQ water might have increased carboxylic acid group 
ionisation, and in addition with the presence of salt, increased water content and its 
hydrophilic property opposing from the collapse usually observed at 32°C - 34°C. This effect 
was even more pronounced in HEPES 5 mM. Microgels containing 20% MAA did not even 
present a clear distinction between the collapsed nor the swollen state. However, this microgel 
increased so much in terms of size that was near reliable limit of the DLS device detection / 
quantification. Since this phenomenon for most microgels was observed, it can be explained 
that without salt but at pH 7.4, electrostatic repulsions within the microgel are so effective that 
it is nearly preventing the microgel to collapse above the LCST of NIPAM. As a result, the 
size variation of microgels (collapsed vs. swelled) in HEPES was caused by reduction in 
NIPAM-co-MAA polymers thermo-sensitivity as seen in fig.S2.1. This hypothesis is also 
supported by the size variation of NIPAM without MAA in HEPES, which exhibited collapse 
similar as in water before its aggregation. The NIPAM aggregation in buffered medium (pH = 
7.4) without salt indicates that the ionic force from HEPES 5 mM was sufficient to initiate the 
aggregation, which is an insight of a very weak colloidal stability. However, this microgel 
might not be very suitable for physiological applications while the addition of MAA in 
NIPAM structure eliminates this concern.  
 
 Additionally, the surface charge of microgels was also influenced by temperature. It 
was observed that increasing the temperature decreased the ZP of the microgels. This behavior 
can be explained considering that upon collapsing the sulfated end chains from the initiator as 
well as MAA are expelled from the core of the microgel thus increasing ZP. This mechanism 
also supports the results observed with NIPAM without MAA, which demonstrated increase in 
ZP from a quasi-neutral charge (-1.8 mV) at 22°C to a more polarized surface (-11.8 mV) at 
38°C. Such ZP decrease was also observed with the other microgels, but to a lower extent. For 
the release studies, microgels were loaded with R6G using the standard loading procedure 
described in the methodology section. DL and LE were determined in milliQ water medium 
and in HEPES 5 mM without salt and were expressed in percentage (table 2.1). Particles with 
no MAA incubated in water and HEPES without salt and particles with 5% MAA incubated in 
water were not tested for release studies in hydrogels since they demonstrated very low DL 
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and LE. Although, very high DL (23.3%) and LE (50.6%) were achieved in HEPES without 
salt after purification using MAA 20% microgels, hence reducing the total particle amount 
needed for reaching 0.27 mg R6G in the hydrogels for release purposes. 
 
2.3.5.1. NIPAM-co-MAA microgels DL and LE characterization 
 To gain more insights into the parameters that influence the microgel's capabilities to 
encapsulate R6G, a complete evaluation of DL and LE as a function of MAA ratio, R6G / 
particle ratio, incubation medium and incubation temperature was performed (see figure 2.4). 
 
 At first, microgels were incubated with R6G at different concentration for 1 hour at 
25°C in pure water. DL was determined for each ratios of MAA in microgels represented in 
figure 2.4A. Noticeably, NIPAM without MAA did not demonstrate significant encapsulation 
of R6G at any R6G ratios in pure water. However, the presence of MAA in the microgel 
structure significantly increased DL and LE from 0% for microgels containing no MAA up to 
16.3% (DL) and 32.4% (LE) for 20% MAA, for instance, at a R6G/Particle ratio of 0.6. As 
can be seen in figure 2.4A, 2.4B, and in table 2.1, by increasing the MAA content in the 
microgel, the DL and LE increased as well. The effect of MAA concentration in microgels on 
DL and LE was also found (quite well) correlated with the effect of MAA on ZP. Likewise, 
increasing the drug per particle ratio increased DL up to a ratio of 0.6 then decreased 
afterward, meaning that maximum loading reached at this ratio. Above 0.6 ratio, LE decreased 
as well, as shown in figure 2.4B, indicating that there was an increasingly higher concentration 
of free R6G remaining after loading, thus increasing the need for extensive purification. 
 
We found that these results were finely correlated with the Langmuir isotherms 
equations. As it was suggested by Grosberg et al. (44), it was possible to determine the 
affinity and the quantity bound to macroscopic hydrogels by adsorption. More recently, 
this equation was applied to microgels and was shown as a promising tool for drug-
microgels interactions models. The Langmuir adsorption isotherm equation is given 
below: 
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𝐷!" = !×!×!!"#!×!!"#!!                                    (Eq. 2.3) 
 
Dad is the concentration (mmol/L) of R6G adsorbed on the microgel, Dsol is the 
concentration (mmol/L) of free R6G remaining in solution, S is the concentration 
(mmol/L) of maximum adsorption and K is the affinity constant of R6G to its 
adsorption site (L/mmol). Using Origin Pro 8.5® we fitted the equations on R6G 
adsorbed concentration in function of free R6G concentration in order to determine S 
and K (figure 2.5A). Since K should be the same for each microgels with content in 
MAA>0% (adsorption site) K was kept constant.  
 
The overall affinity, Q, of R6G to the microgels was calculated by multiplying S 
and K, resulting in unitless value. This value was plotted in function of MAA content in 
microgels (figure 2.5B). The result is the expression of a quasi-proportional linear 
regression supported by Adj-R2 higher than 0.95. The slope indicates that using 
NIPAM microgels containing higher percentage of MAA is directly proportional to 
microgels affinity to R6G. However, as it was observed with the size thermo-sensitivity 
assay, the appearance of nano-domains richer in MAA could alter this correlation at 
higher MAA content in the microgels with more important structure changes. These 
results also supports that the R6G is mostly adsorbed to the microgels by electrostatic 
interaction since its affinity is linearly proportional to the concentration of MAA in the 
microgel if the structures remain similar and loading mediums are identical. 
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Figure 2.4. Characterization of R6G loading in NIPAM-co-MAA microgels. Microgels 
containing 0 to 20% MAA were loaded with R6G in pure water and (a) drug loading and (b) 
loading efficiency were determined at different R6G / particle ratio. Drug loading for MAA 
10% microgels were determined in PBS 10 mM with 145 mM NaCl (pH = 7.4), pure water 
and in HEPES 5mM without salt (pH = 7.4) at (c) different R6G / particle ratio and at (d) 
different static temperatures and temperature cycles. If not mentioned, incubation temperature 
was set to 25oC for one hour. 
 
  
 Different temperatures and different incubation media were also evaluated in terms of 
DL using one microgel formulation (MAA 10%) as illustrated in figure 2.4C and 2.4D. In 
HEPES 5 mM  (pH = 7.4) we observed a high level of loaded R6G (38%) compared to pure 
water (pH = 5.5). We hypothesized that this increase is mostly due to effect of pH being 
higher in HEPES, increasing ionization of COOH groups and therefore increasing electrostatic 
interaction between R6G and the COO- present in the microgel. This is supported by reported 
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values of pKa of the microgels containing MAA between 5 and 6 (45). Consequently, 
switching from a medium at pH = 5.5 to pH = 7.4 would lead to an increase in ionization of 
the COOH groups in the microgels. No peak or plateau was reached in terms of DL in HEPES 
5 mM at ratios from 0.2 to 0.8, meaning, achieving higher DL with R6G/particle ratio higher 
than 0.8 should be possible. The addition of salt further confirmed the fact that electrostatic 
interactions are the primary interactions responsible for drug loading. DL in PBS 10 mM and 
NaCl 145 mM at pH = 7.4 was close to 0% and compared to both media previously described 
was significantly reduced for every R6G/Particle ratio used, the latter having no effect on DL 
in buffered saline. 
 
 Additionally, the affinity Q, of R6G on microgels using all three different incubation 
media was determined using K and S parameters from Langmuir isotherm as described 
previously. Resulting affinity Q was compared with all three media used for loading (figure 
2.5C). The calculated affinity for milliQ water (pH = 5.5) was evaluated at 1.1 ± 0.3, 
phosphate 10 mM with NaCl 145 mM at 0.04 ± 0.04 and HEPES 5 mM at 6.4 ± 0.5. Without 
presence of ions and at slightly acidic pH affinity was almost 6-fold lower compared to a pH 
of 7.4 with the presence of very few ions, supporting an ionization of the COOH groups in the 
microgel. However, by increasing the concentration of counter-ions such as NaCl, the affinity 
for microgel decreases drastically. 
The thermo-sensitivity of microgels was tested to investigate the potential for 
increasing the drug loading capabilities by successive swelling and collapsing cycles (39, 46). 
This process had the potential to maximize the penetration of R6G within the core of the 
particle thus increasing DL. Using three different incubation media (pure water, HEPES 5 mM 
and PBS 10 mM + NaCl 145 mM), incubation temperatures of 25°C and 40°C and incubation 
temperature cycles of 0-40-0°C and 25-40-25°C, no significant differences on DL were found 
for each temperature, as illustrated in figure 2.4D. This result suggests that the inner and outer 
parts of the microgel quickly equilibrate. The Langmuir isotherm was not applied since no 
variation of DL was observed for all temperatures assayed. The Langmuir isotherm was not 
applied since no variation of DL was observed for all temperatures assayed.  
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Figure 2.5. Characterization of R6G affinity to microgels. Langmuir isotherms for microgels 
(A) for 3 microgels, where the affinity Q was determined and plotted in function of MAA 
concentration (B). The affinity for R6G to microgels are also presented in three mediums and 
conditions (C). 
 
2.3.6. In vitro release from hydrogel embedding microgels or nanogels 
 The release kinetic of NIPAM-co-MAA microgels and chitosan-HA nanogels 
embedded in AAm/BisAc hydrogel was followed over 72 hours at 4°C and 37°C as presented 
in figure 2.6. The drug release studies were all performed in a HEPES buffer (HEPES 5 mM + 
NaCl 145 mM). 
 The release curves of the different embedded microgels can be explained by two 
different release behaviours (figure 2.6A). The initial release shows a constant first-order 
release kinetic suggesting an affinity-based release. Thereafter, a much slower release rate is 
observed after a 60-70% cumulative release of R6G. This “break point” was calculated by 
drawing the release linear curves for both release kinetics on OriginPro 8.5®. The “break 
point” was determined where both release curves cross for each microgels formulations in 
table 2.2. 
Loaded in HEPES 5mM, the tested microgel formulations initially released 58-82% of 
the R6Gs within 5 to 25 hours at 37°C, until reaching the “break-point”, as shown in table 2.2. 
The release kinetics of R6G from microgels loaded in pure water were also evaluated in 
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HEPES buffer for 72 hours (figure 2.6B). Each tested formulation demonstrated similar initial 
release profiles with 64-71% released in 4 to 8 hours (table 2.2). Hydrogels containing free 
R6G initially released slightly faster in comparison to hydrogels embedded with microgels, 
which release their contents over 4-8 hours (63-66%) in comparison. Despite a fast release at 
37°C, hydrogels embedded with microgels loaded in HEPES show the potential to sustain 
release up to 10.7 hours compared to hydrogels containing free R6G since the “break point” 
was reached after only 4 hours. Similarly, embedded microgels loaded in pure water also 
reached the “break point” at 8.3 hours. The results suggest that the R6G loading medium did 
not impact the R6G release rate nor its release mechanism. Additionally no clear correlation 
between release rate and the MAA ratio in microgels was observed. However, the presence of 
microgels could be responsible for the reduced release rate. 
 
 
Figure 2.6. Release kinetics of microgel and nanogel formulations embedded in hydrogel 
structures at 4oC and 37oC. (a) Release kinetics of R6G were followed for 72 hours for each 
microgel formulations loaded with R6G in HEPES 5 mM without salt and (b) in pure water. 
Release of sulforhodamine B from nanogels was also studied along with microgels initially 
loaded in water. 
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For the purpose of studying temperature effects and release mechanism on drug 
release, R6G release was also evaluated at 4°C for 72 hours (figure 2.6B). It was found that 
R6G initially released (loaded in HEPES 5 mM) 58- 72% for each microgel after 
approximately 11 - 25 hours (table 2.2). Comparatively, the microgels loaded in pure water 
released 64-69% of its total contents in 7-9 hours and free R6G released 65.8% within 7.6 
hours until the “break point”. Release results at 4°C also support the hypothesis that increased 
sustained release using microgels allow for an extra 3-17 hours of release (microgels loaded in 
HEPES for instance) compared to free R6G. Likewise, temperature increased the rate at which 
the “break point” was reached at 4°C compared to 37°C. This effect is independent of the R6G 
initially loading medium (Figure 2.6A and 2.6B). This can be explained by the reduced 
solubility of R6G in buffered saline at 4°C, decreasing its mobility through the hydrogel 
network. In addition, the thermo-sensitivity of microgels might have influenced the release 
rates. Since the hydrogel is polymerized at room temperature the microgels are swollen, but at 
release temperature of 37°C, it shrinks, expelling R6G from its shell and leaving a 
“micropore” network within the hydrogel, thus facilitating R6G release. In comparison, this 
phenomenon would not occur at 4°C since microgels would remain in a swelled state. 
Release from chitosan and HA nanogels was performed by the same method. The 
incubation at both 4°C and 37°C, cumulative release (CR) of sulforhodamine B was evaluated 
over 72 hours. The resulting release kinetics represented in figure 2.6B was compared with 
hydrogels containing free sulforhodamine B (figure 2.6B). Chitosan nanogels released 
sulforhodamine B in a more controlled fashion than its free form. Nanogels embedded in 
hydrogels released 73.7±2.0% over a period of 48 hours at 37°C and 64.4±3.8% in the same 
timeframe at 4°C, while 85.8±7.1% and 77.9±6.4% of free sulforhodamine B were released 
from hydrogel at 37°C and 4°C respectively within 24 hours. Although a high burst effect (21-
29%) can be observed initially from embedded nanogels, suggesting an immediate release of 
sulforhodamine B upon swelling in the incubation medium. Conversely, lowering temperature 
decreased the release rate by reducing the CR by 9% at 4°C in nanogel systems embedded in 
hydrogel. The results suggest that embedding nanogel significantly impacted the release 
profiles of the sulforhodamine B from the hydrogels by altering its release pattern in more 
controlled fashion.  
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2.3.7. Release profiles from hydrogels embedding liposomes and microgels 
The inclusion of three different formulations of nanocarriers within hydrogels and their 
different release profiles are multiples factors related. Liposomes usually are a layer or bi-
layer of phospholipids with different compositon where they can entrap hydrosoluble drugs 
within their hollowed structure. Nanogels and microgels are made from hydrophilic polymers 
swelled in water and can also encapsulate / adsorb drugs. Differences in the encapsulation or 
adsorption properties of nanoparticles lead to major differences in the release kinetics from 
hydrogels. Since the liposomes consist mainly of lipids, the release kinetics from liposomes 
embedded in hydrogel could be estimated by the diffusion coefficient of the drug within the 
liposome bi-layer. Similarly, the release profiles from microgel embedded in hydrogel could 
be also estimated by the affinity of the drug to the microgel. Equation modeling these different 
profiles has been described in recent studies (Eq. 2.4) (47).  
𝑡∗ = !!!!  ×(!!!×!!")                           (Eq. 2.4) 
 
 
Table 2.2. Release curve “break points” for affinity-based systems (microgels and free R6G 
or SRB) 
 
Particle Loading medium Incubation temperature = 37oC Incubation temperature = 4oC 
  Release time (h) % Released Release time (h) % Released 
MAA5% HEPES 5 mM 
Water 
5.0 h 
N.D 
65.1 
N.D 
11.0 h 
N.D 
57.7 
N.D 
MAA10% HEPES 5 mM 
Water 
10.7 h 
7.6 h 
74.8 
71.0 
22.7 h 
8.2 h 
72.6 
66.3 
MAA12.5% HEPES 5 mM 
Water 
5.5 h 
8.3 h 
62.5 
69.0 
11.6 h 
7.0 h 
60.9 
64.3 
MAA15% HEPES 5 mM 
Water 
4.9 h 
4.3 h 
81.6 
70.0 
25.2 h 
9.2 h 
72.4 
68.0 
MAA 20% HEPES 5 mM 
Water 
7.2 h 
6.0 h 
78.7 
68.6 
13.0 h 
8.9 h 
70.2 
69.3 
Free R6G N/A 4.0 h 62.5 7.6 h 65.8 
Free SRB N/A 3.9 h 73.6 21.2 h 77.6 
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t* is the adjusted time (adimensional), t is the time (h), L2 is the thickness of the 
hydrogel (48), D is the diffusion coefficient (cm2/s), K is the affinity constant of the 
(mM-1) drug with the particle and CNP as the concentration of particles / binding site 
(mM). 
(Eq. 2.4) was discussed in a study in order to collapse different release profiles from 
nanoparticles embedded within hydrogels into single master curve based on the parameters 
that affect the release rate. These parameters include the diffusion factor (𝑳𝟐𝑫 ) from Fick's 
second law of diffusion and affinity factor (𝟏 + 𝑲×𝑪𝑵𝑷) from Langmuir isotherm eqation. 
We assumed that the affinity of sulforhodamine B to the liposomes does not vary 
significantly with changing phospholipids composition (50:50, 60:40, 70:30). Since 
sulforhodamine B is hydrophilic, most of the sulforhodamine B will be encapsulated within 
the liposome cavity rather than being bound to the lipid bilayer, hence the affinity should be 
<<1.  The time was adjusted using the following simplified equation (Eq. 2.5): 
 𝑡∗ = !×!!!                                       (Eq. 2.5) 
 
The diffusion coefficient of the liposomes embedded in hydrogel was 
determined by calculating the effective diffusion coefficient (Deff) using Fick’s second 
law, where the diffusion in solid may be expressed as in (Eq. 2.6) (49): 
 𝐶𝑅%= 2×(!!"" × !! × !! ) !/!                         (Eq. 2.6) 
 
CR% corresponds to the cumulative release of the drug, t is the time (hour), L2 is 
the thickness of the hydrogels cylinders (5 mm). The release kinetics were fitted using 
this equation and Deff was obtained for each liposome formulations. 
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The application of the equation using the collected Deff (table 2.3) yielded a collapse in 
the release curves of liposomes with all different compositions embedded in hydrogels (figure 
2.7A). This collapse suggests that the observed release kinetics were mostly controlled by the 
coefficient of diffusion, also expressed by the square root release kinetic observed in figure 
2.7A. It was expected that release curves from diffusion-based controlled systems would 
collapse into one curve by adjusting the time through normalizing diffusion coefficient in Eq. 
2.4. Release curves remained collapsed which supports the assumption that K does not vary 
significantly with changing phospholipids composition. Thus, diffusion is the major 
mechanism through which the sulforhodamine B is released. 
In contrast, microgels are most likely to follow an affinity based release profile. 
Microgels embedded in hydrogel release curves were then adjusted using the following 
simplified equation from Eq. 2.4: 
 𝑡∗ = !(!!!×!!"")                         (Eq. 2.7) 
 
Since K was already calculated from Langmuir isotherms, they were directly 
integrated in the equation and time was adjusted with according parameters. We 
omitted the diffusion factor of Eq.2.4 (!!!), since it is the same for every microgel 
formulation.  
 
Resulting curves were quite similar as it initially was, but show better 
superposition range (figure 2.7B). Such results confirm that the presence of the 
microgel does affect the release kinetic but is mostly affected by the affinity of the 
R6G-microgel. Additionally, the differences between the slope at 37°C and 4°C is more 
important, confirming the small temperature effect. The slope variation might be the 
result of a diminished diffusion coefficient in the R6G due to a reduced mobility at 
4°C.  
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Figure 2.7. Release curves time adjustment of liposomes and microgels embedded in 
hydrogels. Adjustment of time in function of hydrogel thickness and diffusion coefficient (Eq. 
2.5) on liposomes (A) and adjustment based on R6G affinity with the microgel loaded from 
both water and HEPES 5mM (B). In comparison with their respective unadjusted release 
curves, an effect of superposition should be created with both adjustments. 
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To summarize, it has been demonstrated that NIPAM-co-MAA microgels have the 
capability to prolong the time of release. More considerably, chitosan-HA nanogels have the 
capacity for a finer control than microgels by one extra day but were not as sensitive to 
temperature. However, use of microgels or nanogels does not sufficiently control the release 
of their active compound to produce the zero-order release kinetic, which is possible with 
liposomes.  
2.4. Conclusion 
 The research goal was to determine a method to produce highly stable liposomes, 
microgels, and nanogels embedded in hydrogels by modifying their compositions and 
concentrations to ensure controlled release of active compounds. We demonstrated the main 
release mechanism of each system and provided methods to better predict and understand the 
key parameters involved in drug-loading and controlled release systems, and how they 
influence the release from a model hydrogel matrix containing nano-inclusions. Affinity-based 
Table 2.3. Diffusion and affinity key parameters for R6G and sulforhodamine B release. 
 
Formulation design 
 
Composition 
 
Deff (cm2/h) 
 
K (mmol/L)-1 
 
 
Liposome 
 
DOPC:DPPC 50:50 
 
 
2.7 
 
- 
DOPC:DPPC 60:40 
 
3.9 - 
DOPC:DPPC 70:30 
 
8.5 - 
Nanogel HA + Chitosan 30.8 0.16 
 
Microgel 
 
NIPAM 
 
 
- 
 
- 
NIPAM-co-MAA 5% 
 75.5 45 
NIPAM-co-MAA 10% 
 75.5 45 
   NIPAM-co-MAA 12.5% 
 75.5 45 
NIPAM-co-MAA 15% 
 75.5 45 
NIPAM-co-MAA 20% 75.5 45 
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nano-inclusions yielded a better drug-loading tuning within the hydrogel but did not sustain 
the rate of active compound release compared to liposomal systems. For the liposome based 
system, it was found that it is easier to adjust the release rate by simply altering lipid 
composition and diffusivity of the active compond. The results also have showed that 
embedding nanocarriers within hydrogels has helped to improve the loaded nanocarriers 
stability and to control the release over time. 
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Chapter 3 : Discussion  
 
3.1. Discussion 
In this study, our objective was to develop an enhanced controlled delivery system 
based on embedding different nanocarriers (liposomes, nanogels, microgels) loaded with 
model active compounds within hydrogels. A structured hydrogel was created with embedded 
nanocarriers separately loaded with model active compounds that would be released in a 
controlled fashion by manipulating different parameters of temperature and nanocarriers’ 
composition and concentration.  
We compared drug loading and release kinetics of sulforhodamine B using liposomes 
composed of DOPC and DPPC at different ratios, nanogels of CS/HA, and the release kinetics 
of rhodamine 6G using NIPAM microgels with different ratios of MAA embedded in a model 
hydrogel of acrylamide. 
 Performing the release study from liposomes alone or embedded in hydrogels at 4°C 
has helped to maintain and decrease the release rate of sulforhodamine B significantly 
compared to 37°C in the (50:50) formulation but less efficiently in (60:40) and (70:30) 
formulations (figure 2.1A and figure 2.2A). The difference in release rate between the 50:50 
formulation at various temperatures suggests a significant influence towards temperature. This 
can be explained by DOPC phospholipid having very low transition temperature (-22°C) 
comparing to release conditions and at 37°C it is relatively close to transition temperature of 
DPPC phospholipid (41°C) which lead to liposomes permeation. Temperature has greater 
influence over formulations of (60:40) and (70:30) due to presence two different components 
of phospholipids with higher component of DOPC (1, 2). Liposome stability is directly related 
to lipid acyl chain type, which is consequently related to variability of phase transition 
temperatures (3). As a result, the liposomal phospholipids membrane barrier efficacy will 
significantly change near phase transition temperatures (4). So, higher levels of DOPC provide 
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higher release rate from liposome because of gap between media temperature of 4°C and 37°C 
in comparison to DOPC transition temperature that will lead to decreasing liposomes surface 
stability and increasing leakage rate. Our results are in agreement with a study, which showed 
that using higher rigid phospholipid components with higher transition temperatures is directly 
related to more stable liposomes and decreased diffusion rate of active compound (5).  
All three liposome formulations have shown different DL and LE capabilities, which 
may have influenced the release rate from liposomes. Our results showed that the highest DL 
and LE were obtained in the (50:50) formulation while the lowest DL and LE were obtained 
from the (70:30) formulation (table 2.1). These findings suggest that 50:50 formulation is 
optimal to achieve the best sulforhodamine B loaded liposomes because of higher 
encapsulation rates associated with higher DPPC content preventing loaded molecules from 
being leaked. The variations in DL and LE could be due to the change in the liposome 
membrane fluidity, which depends on differences in both the phospholipid composition and 
phase transition temperature. 
Comparatively to liposomes, in NIPAM-co-MAA microgels using higher MAA ratios 
has resulted in higher DL and LE (table 2.1). This was occurred due to an increased negative 
charge on the surface of microgels and consequently more binding affinity of positively 
charged R6G. In contrast, using lower ratios of MAA has seemed to provide slower release 
rate of R6G but there has been no clear corelation explaining that in this study (table 2.2). 
Results showed that the release rate of R6G from microgels embedded in hydrogels was 
higher at 37°C regardless loading medium because of microgels thermo-sensitivity. However, 
better controlled release rate was achieved at 4°C from microgels loaded with R6G in HEPES 
buffer because they maintained their swelled state for longer period comparing 37°C (table 
2.2).  
In nanogels, results revealed that they had high DL and LE due to presence of positive 
charge on their surface, which enhanced negatively charged sulforhodamine B loading (table 
2.1). Performing the release under varying thermal conditions had a mild influence over the 
release rate of sulforhodamine from nanogels embedded in hydrogels since they are not 
thermosensetive (figure 2.6B). The mild variation in release rate at different temperatures 
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could be due to the change in medium viscosity that affect sulforhodamine B solubility and 
mobility through the hydrogel networks. 
The release kinetics from liposomes were estimated by the diffusion coefficient of the 
sulforhodamine B loaded within the liposomes phospholipids bilayer and embedded in 
hydrogel. Similarly, release profiles from microgels embedded in hydrogels were estimated by 
the affinity of the R6G to microgels and its diffusion from hydrogel scaffolds. Results 
obtained from each controlled delivery system depended either on diffusion-based release 
(liposomes), or affinity-based release (microgels, and nanogels) suggest that all systems have 
achieved extended release duration (section 2.3.7). However, the controlled release system 
based on hydrogel embedding liposome has shown a higher extended release duration 
comparing to the other two systems, which makes it the optimal system for controlled release 
purposes.  
Developing an alternative polymerizing technique other than photopolymerization 
based on UV exposure might alter the release rate resulting in a better controlled release from 
hydrogel embedding liposomes system. We tested the 60:40 formulation release behavior 
before and after exposure to UV radiation. We found that there was increased sulforhodamine 
B leakage and release (figure 2.1B). This could be due to the thermal energy produced by the 
lamp and led to liposome surface permeation and consequently increased release rate. Another 
explanation for such behavior could result from oxidation of DOPC double bonds and 
changing liposome uniformity since this phospholipid is present in higher concentrations.  
Changing phospholipids composition of liposomes could alter the release rate due to 
changes that will occur in liposomal stability (5), DL, and LE. Using different hydrogel type 
and varying its crosslinking rates might improve its biocompatibility, and rheological 
properties that could impact nanocarriers controlled release of active compounds (6, 7). 
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Conclusion 
The research aimed to develop an improved active compound controlled delivery 
system by combining two active compound carriers in order to overcome limitations observed 
in the individual carriers such that it would lead to an enhanced controlled release delivery 
system. We have developed a structured hydrogel with embedded liposomes, microgels, and 
nanogels loaded with model active compounds that would be released in a controlled fashion 
by modifying thermal conditions and nanocarriers composition and concentration. We 
prepared and optimized three liposomes formulations using DOPC and DPPC phospholipids 
with different ratios loaded with sulforhodamine B. The release of sulforhodamine B from 
liposomes, hydrogel, and hydrogel embedding liposomes and varying thermal conditions was 
performed to evaluate the effects of temperature and varying phospholipids concentrations 
over sulforhodamine B release rate.  
Results showed that liposome formulation with higher DPPC ratios provided better 
extended release duration comparing to formulations with higher DOPC ratios. Upon 
embedding these formulations separately loaded with the sulforhodamine B, within 
acrylamide hydrogels with fixed crosslinking rate resulted in a controlled release rate of 10 
days. Using the same quantity of sulforhodamine B loaded within the hydrogel alone resulted 
in releasing most of the content within 48 hours only under the same thermal conditions. 
Embedding microgels with different ratios and nanogels separately into hydrogels loaded with 
same quantity of rhodamine 6G and sulforhodamine B respectively as in liposomes, resulted in 
faster release compared to embedded liposomes. Adjustment of hydrogel-liposomes based 
system via modifying phospholipids composition ratios provides the slowest release rate in 
comparison to microgels and nanogels. These findings suggest that diffusion-based release 
systems (liposomes) have higher potential than affinity-based release systems (microgels and 
nanogels) to achieve better controlled release. Embedding different nanocarriers within 
hydrogels has proven to be advantageous in providing a solution for increasing the stability of 
nanocarriers and hydrogels toward achieving an improved controlled release delivery system
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Appendix 
A 
B C 
Figure S2.1. Entire microgels particle size characterizations results. Particle size, represented by Z-ave, 
characterization of NIPAM-co-MAA microgels in (A) pure water, (B) PBS 10 mM and 145 mM NaCl 
(pH=7.4) and (C) HEPES 5mM (pH = 7.4). Error bars may not be fully distinguishable for each microgels. 
NIPAM without MAA aggregates at 32°C resulting in high PS increases. 
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Figure S2.2. Entire microgels zeta potential characterizations results. NIPAM-co-MAA 
microgel zeta potential in 4 mM NaCl solution at 22°C and 38°C. 
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